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Abstract 
 
Purpose: Understanding etiologic heterogeneity of ovarian cancer is important for improving 
prevention, early detection and therapeutic approaches. We evaluated 14 hormonal, reproductive, 
and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3). 
 
Patients and Methods: Among 1.3 million women from 21 studies, 5,584 invasive epithelial 
ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 
1,000 other). Using competing risks Cox proportional hazards regression stratified on study and 
birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for 
all invasive cancers and by histology. Heterogeneity was evaluated by likelihood ratio test. 
 
Results: Most risk factors exhibited significant heterogeneity by histology. Higher parity was 
most strongly associated with endometrioid (RR, per birth=0.78; 95% CI=0.74-0.83) and clear 
cell (RR=0.68; 95%CI=0.61-0.76) carcinomas (p-het<0.0001). Similarly, age at menopause, 
endometriosis, and tubal ligation were only associated with endometrioid and clear cell tumors 
(p-het=0.009). Family history of breast cancer (p-het=0.008) had modest heterogeneity. Smoking 
was associated with increased risk of mucinous (RR, per 20 pack-years=1.26; 95% CI=1.08-
1.46), but a decreased risk of clear cell tumors (RR=0.72; 95% CI=0.55-0.94) (p-het=0.004). 
Unsupervised clustering by risk factors separated endometrioid, clear cell, and low grade serous 
carcinomas from high grade serous and mucinous carcinomas. 
 
Conclusion: The heterogeneous associations of risk factors with ovarian cancer subtypes 
emphasize the importance of conducting etiologic studies by ovarian cancer subtypes. Most 
established risk factors were more strongly associated with non-serous carcinomas, 
demonstrating challenges for risk prediction of serous cancers, the most fatal subtype. 
Introduction 
 
 
Ovarian cancer is the most lethal gynecologic cancer, with over 152,000 deaths world-wide each 
year (1). Most ovarian cancers are detected at late stage and have a poor prognosis. Screening for 
ovarian cancer did not reduce mortality in two large screening trials (2, 3). Understanding the 
etiologic heterogeneity of ovarian cancer is critical for development of new prevention strategies. 
 
Although multiple carcinogenic mechanisms for ovarian tumorigenesis have been hypothesized, 
including incessant ovulation, hormonal stimulation, and chronic inflammation (4-7), the 
etiology of ovarian cancer is not well understood in part due to its heterogeneous nature. Disease 
subtypes have been categorized by putative precursor lesions, mutations, and histology (8, 9). 
Low-grade serous, mucinous, clear cell, and endometrioid tumors are thought to arise from 
inclusion cysts or implants in the ovarian surface epithelium and have K-RAS, B-RAF, or P-TEN 
mutations. High-grade serous tumors, characterized by TP53 mutations, are thought to arise in 
the fallopian tube or ovarian epithelium, are more aggressive and have poorer outcomes than 
other types (8-10). Due to limited power, individual epidemiologic and biomarker studies 
usually have considered risk factor associations for all ovarian tumors together. Recently, 
individual cohorts and individual-level meta-analyses of primarily case-control studies have 
reported differential associations by subtype for menopausal hormone therapy (HT) use, oral 
contraceptive (OC) use, parity, smoking and body mass index (BMI) (11-17). To establish 
etiologic models accounting for ovarian cancer heterogeneity, there is a need for a unified 
prospective evaluation of multiple ovarian cancer risk factors accounting for heterogeneity. In 
the Ovarian Cancer Cohort Consortium (OC3) we evaluated associations of 14 key risk factors 
with invasive epithelial ovarian cancer risk overall and by histologic subtype based on pooled 
individual-level data from 5,584 invasive ovarian cancer cases from a combined cohort of over 
 
1.3 million women enrolled in 21 studies. 
Methods 
 
 
Study population 
 
 
The analysis included women participating in 21 prospective cohort studies from North America, 
Asia, and Europe (Table 1). Prospective follow-up of ovarian cancer endpoints through 
questionnaires, medical records or cancer registries, as well as follow-up for death were required 
for participation. Minimal required information included age at study entry, OC use, and parity. 
All studies obtained institutional approval for cohort maintenance and participation in the OC3. 
The OC3 Data Coordinating Center and analytic approaches were approved by the institutional 
review board of the Brigham and Women’s Hospital (BWH). 
 
Exposure definitions 
 
 
Full baseline cohort data (19 studies) or case-cohort datasets with weights for subcohort members (2 
studies) were harmonized centrally. Exposures included: parity (ever vs. never, number of births: per 1 
birth; 1, 2, 3, 4+ births), OC use (ever vs. never, duration of use: per 5 years of use; never, ≤1, 
>1-≤5, >5-≤10, >10 years), duration of breastfeeding (per 1 year among parous women), age at 
menarche (per 1 year; ≤11, 12, 13, 14, ≥15 years), age at natural menopause (postmenopausal 
women only: per 5 years; ≤40, >40-≤45, >45-≤50, >50-≤55, >55 years), menopausal HT use 
(ever vs. never, duration of use: per 1 year; never, ≤5, >5 years), tubal ligation (ever vs. never), 
hysterectomy (ever vs. never), endometriosis (ever vs. never), first degree family history of 
breast cancer (ever vs. never), first degree family history of ovarian cancer (ever vs. never), 
BMI (per 5 kg/m2; <20, 20-<25, 25-<30, 30-<35, ≥35 kg/m2), height (per 0.05; <1.60, 1.60-
<1.65, 1.65-1.70, ≥1.70 m), and smoking (ever vs. never, pack-years: per 20 pack-years; ≤10, 
>10-20, >20-35, >35 pack-years). Studies that did not collect information on a 
 
specific risk factor were excluded from the analysis of that factor (Supplemental Table 1), 
 
leading to different samples sizes for each variable (Supplemental Table 2). 
 
 
Outcome definitions 
 
 
Epithelial ovarian or peritoneal cancer cases were confirmed through cancer registries or medical 
record review (ICD9: 183, 158; ICD10: C56). We evaluated associations of risk factors with all 
invasive epithelial cancers combined (n=5,584). Next, we evaluated associations with the four 
most common histologic types of invasive epithelial ovarian cancers (n=4,584): serous/poorly 
differentiated, endometrioid, mucinous, and clear cell. 1,000 cases had another histology or were 
missing histology information. Serous tumors were further subdivided by grade (well-, 
moderately-, poorly-differentiated, unknown). 
 
Statistical methods 
 
 
Women with a history of cancer (other than non-melanoma skin cancer), with bilateral 
oophorectomy prior to study entry, or missing age at baseline were excluded. We calculated 
hazard ratios (HR) and 95% confidence intervals (95% CI) using competing risks Cox 
proportional hazards regression to evaluate associations between exposures and ovarian cancer 
endpoints (18). Follow-up time was time between study entry and date of 1) ovarian cancer 
diagnosis, 2) death, or 3) end of follow-up, whichever occurred first. In primary analyses, we 
pooled data from all cohorts, and stratified on year of birth and cohort to account for potential 
differences in baseline hazards by these factors. Statistical heterogeneity of associations across 
subtypes was assessed via a likelihood ratio test comparing a model allowing the association for 
the risk factor of interest to vary by histology versus one not allowing the association to vary 
(16). We also used random effects meta-analysis to combine cohort-specific estimates and assess 
 
between-study heterogeneity. All models were adjusted for age at entry, number of children, and 
duration of OC use, unless the exposure of interest was collinear with these factors. 
Hysterectomy analyses were additionally adjusted for HT use. For missing data in covariates, we 
included a missing indicator in the model. The Sister Study was excluded from analyses of 
family history as all participants had a family history of breast or ovarian cancer. To evaluate our 
primary models sufficiently accounted for confounding, we performed a model adjusting for all 
exposures together (using missing indicators when needed). In 17 studies, grade was available 
for at least some serous cases. We conducted similar analyses among serous tumors comparing 
risk factors for well-, moderately-, and poorly-differentiated tumors, and unknown grade. We 
performed unsupervised hierarchical clustering of the four subtypes (with and without separating 
serous tumors by grade) using beta estimates for all exposures except for duration of 
breastfeeding (not significantly associated with any of the 4 subtypes) using complete linkage 
and uncentered correlation (Pearson’s coefficient). SAS 9.1 was used to conduct the analyses and 
a p-value of <0.05 was considered statistically significant. 
Results 
 
 
Study population 
 
 
Among 1,284,586 participants (1,381,275 including full cohort size for case-cohort studies), 5,584 
invasive epithelial ovarian cancers were identified during follow-up. Case numbers ranged from 
1,281 for breastfeeding to 5,523 for OC use (Supplemental Table 2). There were 3,378 (73.7% of 
cases with known histology) serous, 606 (13.2%) endometrioid, 331 (7.2%) mucinous, and 269 
(5.9%) clear cell carcinomas. Fifteen of 21 cohorts were based in North America, five in Europe, and 
one in Asia (Table 1); about half of the cohorts started enrollment in the 1990s. The median age at 
diagnosis was 67.0 years for serous, 63.0 years for endometrioid, 64.0 years for mucinous, 61.3 years 
for clear cell carcinomas, and 68.9 years for cases with unknown histology. 
 
Associations of hormonal and reproductive factors 
 
 
Most reproductive and hormonal risk factors, except for breastfeeding, were associated with 
ovarian cancer risk overall (Table 2). Parous versus nulliparous women had a reduced risk of all 
ovarian cancer subtypes, with significant heterogeneity by subtype (p-het=8.47x10
-10
). The 
strongest risk reduction was observed for clear cell (RR: 0.35; 95% CI: 0.27-0.47) carcinomas, 
while serous cancers had the least risk reduction (RR: 0.81; 95% CI: 0.73-0.90). Similar patterns 
were observed for number of children (p-het=4.71x10
-13
). In subtype-specific analyses, a five 
year increase in duration of OC use was associated with significant 14-15% lower risk of serous, 
endometrioid, and clear cell carcinomas, but not with mucinous tumors (p-het=0.04). Similarly, 
OC use >10 years was associated with a 36-49% reduction in risk for serous, endometrioid, and 
clear cell tumors. 
 
A 5-year later menopause was associated with endometrioid and clear cell carcinomas (RR: 1.19; 
95% CI: 1.05-1.34 and 1.37; 95% CI: 1.15-1.64, respectively), with no association for serous and 
mucinous carcinomas (p-het=0.009). A five-year increase in menopausal HT use was associated 
with an increased risk of serous (RR: 1.21; 95% CI: 1.17-1.25) and endometrioid (RR: 1.25; 95% 
CI: 1.15-1.36), but a reduced risk of clear cell (RR: 0.69; 95% CI: 0.52-0.92; p-het=0.00006) 
carcinomas. Tubal ligation was only associated with reduced risk of endometrioid (RR: 0.60; 
95% CI: 0.41-0.88) and clear cell (RR: 0.35; 95% CI: 0.18-0.69; p-het=0.0005) carcinomas, 
while hysterectomy was associated with increased risk of serous (RR: 1.18; 95% CI: 1.07-1.29) 
and decreased risk of clear cell carcinomas (RR: 0.62; 95% CI: 0.41-0.96; p-het=0.005). Self-
reported endometriosis was significantly associated only with endometrioid (RR: 2.32; 95% CI: 
1.36-3.95) and clear cell carcinomas (RR: 2.87; 95% CI: 1.53-5.39; p-het=0.01). There was no 
significant heterogeneity in associations by histology for breastfeeding or age at menarche, 
although the latter was significantly inversely associated with clear cell carcinomas. 
 
Associations of other risk factors 
 
 
Family history of both breast and ovarian cancer and height, but not smoking or BMI were 
significantly associated with ovarian cancer risk overall (Table 3). A first degree family history 
of breast or ovarian cancer was associated with an increased risk of serous tumors (RR: 1.13; 
95% CI: 1.02-1.26; p-het=0.31; RR: 1.61; 95% CI: 1.32-1.97; p-het=0.008, respectively). Family 
history of breast cancer was also associated with endometrioid carcinomas (RR: 1.47; 95% CI: 
1.15-1.87). BMI was not significantly associated with ovarian carcinomas overall or with any 
subtype, although there was a borderline association with endometrioid carcinomas (RR per 5 
kg/m
2
: 1.07; 95% CI: 0.99-1.16). Ever smoking was associated with mucinous carcinomas only 
 
(RR: 1.27; 95% CI: 1.01-1.59); each 20 pack-years of smoking was associated with an increased 
risk of mucinous and a decreased risk of clear cell carcinomas (p-het=0.002). 
 
Associations by subtypes of serous carcinomas 
 
 
Among serous tumors, moderately- and poorly differentiated carcinomas had similar 
associations, while associations for well-differentiated carcinomas were qualitatively different. 
However, the heterogeneity was not significant for most individual factors (Table 4). For 
example, endometriosis was significantly associated with well-differentiated carcinomas (RR: 
3.77; 95% CI: 1.24-11.48), but not poorly-differentiated carcinomas (RR: 1.11; 95% CI: 0.70-
1.74; p-het=0.12). Similarly, >5 years of HT use versus never was associated with a 2.9-fold 
higher risk of well-differentiated carcinomas, but only a 80% higher risk of poorly-
differentiated carcinomas (p-het.=0.45). 
 
Meta-analysis and heterogeneity across studies 
 
 
Results for meta-analyses were similar to the pooled analyses (Supplemental Table 3). We 
observed little heterogeneity in associations across studies (p<0.01 for only 20 of 188 
comparisons). Sixteen of these were for continuous variables, but the categorical associations did 
not show heterogeneity. Family history of ovarian cancer showed heterogeneity for all 4 
subtypes across studies, likely due to the small number of exposed cases in many studies. Results 
were similar when including women with a history of cancer at baseline or when all exposures 
were included in the model (data not shown). 
 
Integrated analysis of risk factors in ovarian cancer subtypes 
 
Each subtype had unique patterns of risk factor associations (Figure 1). The strongest 
associations for most factors were observed for endometrioid and clear cell tumors. 
Unsupervised clustering divided the four histologic subtypes into two major groups (Figure 1A). 
Serous carcinomas were separate from the other three subtypes (Pearson correlation 0.18). 
Endometrioid and clear cell carcinomas had the most similar risk factor associations (Pearson 
correlation 0.70). When serous cancers were subdivided by grade (Figure 1B), they were split 
into two distinct groups: Well differentiated serous carcinomas clustered with endometrioid 
carcinomas (Pearson correlation 0.76), while moderately and poorly differentiated serous 
carcinomas clustered together (Pearson correlation 0.90). 
Discussion 
 
 
In a large pooled analysis of over 1.3 million women, we investigated 14 established or putative 
risk factors in ovarian cancer subtypes. Nine risk factors had significant heterogeneity across 
subtypes. Most reproductive and hormonal risk factors had stronger associations with 
endometrioid and clear cell carcinomas compared to the other types. Serous and poorly 
differentiated carcinomas, the most common and aggressive subtype, had modest associations 
only with parity, OC use, menopausal HT use, and family history of breast cancer, and stronger 
associations with family history of ovarian cancer. 
 
Our analysis represents the largest comprehensive and prospective evaluation of ovarian cancer 
risk factors by histologic subtypes. Our results are consistent with previous reports from 
individual prospective studies within the OC3 (i.e., NHS/NHSII, AARP, EPIC) (15-17). 
However, individually these studies were underpowered to assess subtype-specific 
associations, particularly for rare types. Previously, other consortia, largely based on case-
control studies, reported subtype-specific associations for individual risk factors (12-14, 19-21) 
similar to what we observed. 
 
Models of ovarian carcinogenesis have separated epithelial tumors into major pathways with 
distinct cells of origin, carcinogenic pathways and histology with different clinical behavior (8, 
10). An integrated evaluation of ovarian cancer risk factors by subtypes is important to 
understand factors that drive these etiologic pathways on the population level. Each subtype had 
a qualitatively unique pattern of associations, and serous carcinomas were clearly separated 
from endometrioid, clear cell, and mucinous carcinomas. While endometrioid and clear cell 
carcinomas had qualitatively similar associations for 9 risk factors, they differed in associations 
 
related to HT use (which went in opposite directions), family history of breast cancer (associated 
with endometrioid only), as well as age at menarche, hysterectomy, and smoking (associated 
with clear cell only). Every reproductive/hormonal factor was significantly associated with clear 
cell tumors, except breastfeeding. 
 
Our results suggest that currently hypothesized, unifying mechanisms, such as incessant 
ovulation (4), do not apply equally to ovarian cancers. Several variables that determine a 
woman’s lifetime number of ovulations had significant heterogeneity across subtypes. Only 
parity and height were associated with all subtypes, suggesting a common biologic effect (22). 
Notably, mucinous tumors were not associated with any ovulation-related factors except 
parity, suggesting a more distinct etiology. 
 
Ovarian cancer subtypes share some risk factors with other cancer sites. The inverse association 
between smoking and clear cell ovarian carcinomas is similar to that for endometrial cancer (23). 
Mucinous ovarian cancers share histologic appearance and an association with smoking with 
colorectal cancers (24). Serous ovarian cancers had weaker associations with most hormonal and 
reproductive factors compared to non-serous cancers (with the exception of OC use), similar to 
associations for hormone receptor negative breast cancers (25). These similarities of risk factor 
associations across cancers mirror molecular data showing that tumor subtypes from different organs 
may be more similar to each other on the molecular level compared to other subtypes at the same site 
(e.g., high-grade serous ovarian cancer and basal-like breast cancer) (26). 
 
While the subtype-specific associations observed in our study strongly corroborate the etiologic 
heterogeneity of ovarian cancers, a purely histology-based classification of endpoints may have 
limitations (27). Histologic evaluation is subjective and pathology practice changes over time, 
 
which could affect subtype distributions by location and year of diagnosis. We observed the most 
heterogeneity between studies for mucinous tumors, possibly related to temporal and geographic 
differences in defining mucinous tumors. However, overall, we did not observe significant 
differences in subtype proportions across studies or over time (data not shown). Unsupervised 
clustering demonstrated that well-differentiated serous carcinomas are distinct from higher grade 
serous carcinomas, and group with endometrioid carcinomas. This is important etiologically and 
further supports differentiating these two groups of serous carcinomas, as proposed in models 
based on somatic mutations (REF). However, in population-based studies, grade reported on 
pathology reports may not be reliable and low-grade serous carcinomas account for only about 
5% of all serous cancers (28), limiting potential misclassification when considering associations 
for all serous carcinomas together (29). Analyses by tumor aggressiveness and tumor dominance 
have also shown differences in risk factor associations, indicating that there may be important 
biological heterogeneity beyond histological subtypes (30, 31). Further, additional molecular 
subgroups have been described within high-grade serous ovarian cancers (32, 33), but thus far, 
based on small studies, these subtypes have shown only limited heterogeneity in risk factor 
associations (34). 
 
In summary, we conducted the largest integrated prospective analysis of ovarian cancer risk 
factors to date. Most factors showed heterogeneity across histologic subtypes and each subtype 
had unique patterns of risk factor associations. Our results have important implications with 
respect to etiology and prevention of ovarian cancers. Oral contraceptives continue to be an 
important preventive factor for most types of ovarian cancer. Few other risk factors for ovarian 
cancer are modifiable and those that are, like smoking and obesity, did not show clear associations 
with serous carcinomas, the most common and fatal subtype. The substantial 
 
heterogeneity of individual risk factor associations across ovarian cancer subtypes supports that 
subtypes are indeed different diseases and underscores the importance of evaluating risk factors 
and biomarkers by ovarian cancer subtypes. Our work has implications for the development of 
risk prediction models, which generally consider ovarian cancer as a whole (35): due to weaker 
associations observed for high grade serous carcinomas, prediction of the clinically most 
important subtype may perform worse than for other types, underscoring the importance of 
finding better risk markers for serous carcinomas. Evaluation of subtype-specific risk factor 
associations is important for better understanding of ovarian cancer etiology and for targeted 
development of novel prevention approaches; these analyses require pooling of data across many 
studies in consortia. 
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Figure legend: 
 
 
Figure 1: Unsupervised hierarchical clustering of ovarian cancer histologic subtypes by 
their associations with risk factors 
 
Unsupervised hierarchical clustering of the (A) four subtypes and (B) including the serous 
subtype subdivided into well- moderately- and poorly differentiated carcinomas using the beta 
estimates, complete linkage, and an uncentered correlation similarity metric. The categories 
used in the cluster analysis were ever vs. never parous, ever vs. never OC use, ever vs. never 
tubal ligation, ever vs. never endometriosis, age at menarche >15 years vs. <=11 years, age at 
menopause <40 years vs. 50-55 years, ever vs. never menopausal HT use, ever vs. never 
hysterectomy, family history of breast cancer (yes vs. no), family history of ovarian cancer (yes 
vs. no), BMI >35 vs. 20-25, height (per 5cm increase) and ever vs. never smoking. The color 
scale shows the range of beta values for each exposure. 
 
 
 
 
Table 1: Characteristics of cohorts participating in the Ovarian Cancer Cohort Consortium  
Study name Study Location Baseline Baseline Median study Median Last year of Invasive 
 abbreviation  enrollment cohort participant follow-up follow-up ovarian 
   period sizea age (years)  cancer cases 
NIH-AARP Diet and Health Study AARP U.S. 1995-1997 153,069 62 11 2006 703 
         
Breast Cancer Detection Demonstration BCDDP U.S. 1987-1989 36,212 61 9 1999 159 
Project Follow-up Study         
Breakthrough Generations Study BGS UK 2001-2014 101,869 48 6 2014 75 
         
Canadian Study of Diet, Lifestyle, and CSDLH Canada 1991-1999 2,745
b 
58 16 2010 90 
Health         
Campaign against Cancer and Stroke CLUEII U.S. 1989 12,382 46 22 2012 82 
         
Cancer Prevention Study II Nutrition CPSII-NC U.S. 1992-1993 65,884 62 15 2009 533 
Cohort         
California Teachers Study CTS U.S. 1995-1999 43,778 50 15 2010 185 
         
European Prospective Investigation into EPIC Europe 1992-2000 263,796 51 13 2010 671 
Cancer and Nutrition Study         
Iowa Women’s Health Study IWHS U.S. 1986 30,537 61 23 2010 263 
         
Multiethnic/Minority Cohort Studyc MEC U.S. 1993-1998 16,474 57 11 2011 75 
Nurses’ Health Study 1980d NHS80 U.S. 1980-1982 86,608 46 16 1998 351 
         
Nurses’ Health Study 1996d NHS96 U.S. 1996-1998 67,530 62 14 2010 417 
Nurses’ Health Study II NHSII U.S. 1989-1990 111,800 35 20 2011 215 
         
New York University Women’s Health NYU U.S. 1984-1991 12,427 49 24 2012 129 
Study         
Netherlands Cohort Study on diet and NLCS Netherlan 1986 2,757
b 
62 17 2003 448 
cancer  ds       
         
Prostate, Lung, Colorectal and Ovarian PLCO U.S. 1993-2002 60,191 62 12 2009 358 
Cancer Screening Trial         
Singapore Chinese Health Study SCHS Singapore 1993-1999 31,939 56 14 2011 95 
         
Sister Study SS U.S. 2003-2009 39,195 55 5 2012 39 
Swedish Mammography Cohort Study SMC Sweden 1997 34,427 60 14 2011 161 
         
VITamins And Lifestyle Cohort VITAL U.S. 2000-2002 28,331 60 10 2011 130 
Women's Lifestyle and Health WLHS Sweden 1991-1992 49,087 40 21 2012 201 
         
Women’s Health Study WHS U.S. 1993-1996 33,548 53 18 2012 204 
         
a
After exclusions for baseline cancers and women with bilateral oophorectomy 
b
These cohorts were included as a case-cohort design, reflecting a total cohort population of 39,618 women for the CSDLH and 62,573 women for the NLCS. Appropriate 
weights for subcohort selection were applied in all analyses. 
c
Including only Caucasian women.  
d
The Nurses’ Health Study was broken into two study periods (1980-June 1996 and July 1996-2010) because the follow-up was nearly twice as long as any other study. We updated the 
exposures in 1996 for that follow-up period. 
Table 2: Associationsa of hormonal and reproductive factors with invasive epithelial ovarian cancer overall and by subtypes in the Ovarian Cancer Cohort 
Consortium  
 All invasive Serous Endometrioid Mucinous Clear cell p-heterogeneity 
 N=5584 N=3378 N=606 N=331 N=269 (between 
Exposure RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) histologic types)
b 
Parity       
Ever/never 0.69 (0.64-0.74) 0.81 (0.73-0.90) 0.48 (0.39-0.58) 0.56 (0.42-0.74) 0.35 (0.27-0.47) 8.47E-10 
Number of children, per 1 child 0.90 (0.89-0.92) 0.93 (0.92-0.95) 0.78 (0.74-0.83) 0.91 (0.84-0.99) 0.68 (0.61-0.76) 1.09E-14 
Number of children       
0 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
1 0.82 (0.43-0.91) 0.86 (0.75-1.00) 0.78 (0.60-1.03) 0.59 (0.38-0.92) 0.67 (0.46-0.98)  
2 0.74 (0.68-0.81) 0.87 (0.78-0.97) 0.49 (0.39-0.62) 0.61 (0.44-0.86) 0.38 (0.27-0.53) 4.71E-13 
3 0.67 (0.62-0.74) 0.82 (0.73-0.92) 0.41 (0.32-0.54) 0.52 (0.36-0.74) 0.29 (0.19-0.43)  
4+ 0.58 (0.53-0.64) 0.72 (0.63-0.81) 0.34 (0.25-0.45) 0.55 (0.38-0.80) 0.14 (0.08-0.25)  
Oral contraceptive use       
Ever/never 0.84 (0.79-0.89) 0.82 (0.76-0.89) 0.89 (0.73-1.07) 1.02 (0.80-1.31) 0.72 (0.55-0.94) 0.25 
Duration of use, per 5 year increase 0.87 (0.84-0.90) 0.85 (0.81-0.89) 0.86 (0.77-0.95) 1.54 (0.93-1.19) 0.86 (0.74-1.00) 0.04 
Duration of use, years       
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤1 0.98 (0.87-1.05) 0.99 (0.88-1.12) 1.01 (0.76-1.35) 0.98 (0.66-1.45) 0.68 (0.42-1.09) 
0.35 >1-≤5 0.86 (0.78-0.92) 0.85 (0.77-0.95) 0.82 (0.64-1.05) 0.84 (0.58-1.21) 0.88 (0.62-1.24) 
>5-≤10 0.77 (0.67-0.84) 0.72 (0.64-0.83) 0.85 (0.64-1.13) 0.91 (0.61-1.37) 0.80 (0.54-1.20)  
>10 0.67 (0.58-0.75) 0.64 (0.54-0.74) 0.64 (0.44-0.93) 1.18 (0.77-1.81) 0.51 (0.29-0.87)  
Duration of breastfeeding, per 1 yearc 0.96 (0.89-1.03) 0.94 (0.86-1.03) 0.85 (0.69-1.05) 0.88 (0.63-1.23) 1.03 (0.81-1.33) 0.64 
Age at menarche       
Per 1 year increase 0.99 (0.97-1.00) 0.99 (0.97-1.02) 1.00 (0.94-1.05) 1.00 (0.93-1.07) 0.92 (0.85-0.99) 0.31 
Age in years       
≤11 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
12 0.92 (0.84-1.00) 0.95 (0.85-1.05) 1.02 (0.80-1.31) 1.15 (0.81-1.65) 0.78 (0.54-1.12)  
13 0.94 (0.87-1.02) 0.99 (0.90-1.09) 0.97 (0.79-1.22) 1.06 (0.76-1.48) 0.79 (0.56-1.11) 0.66 
14 0.93 (0.85-1.03) 0.99 (0.88-1.12) 0.84 (0.62-1.13) 0.97 (0.64-1.47) 0.80 (0.52-1.23)  
≥15 0.88 (0.80-0.97) 0.92 (0.81-1.05) 0.98 (0.73-1.31) 1.13 (0.76-1.66) 0.55 (0.34-0.90)  
Age at menopaused       
Per 5 year increase 1.06 (1.02-1.10) 1.05 (1.01-1.10) 1.19 (1.05-1.34) 0.95 (0.81-1.11) 1.37 (1.15-1.64) 0.009 
Age in years       
≤40 0.89 (0.77-1.03) 0.87 (0.73-1.04) 0.59 (0.34-1.00) 1.31 (0.78-2.20) 0.15 (0.03-0.71)  
>40-≤45 0.80 (0.70-0.91) 0.85 (0.73-1.00) 0.76 (0.51-1.14) 0.77 (0.44-1.33) 0.43 (0.20-0.94) 
0.11 >45-≤50 0.93 (0.86-1.00) 0.96 (0.87-1.06) 0.86 (0.67-1.09) 0.95 (0.68-1.31) 0.95 (0.64-1.39) 
>50-≤55 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
>55 1.02 (0.89-1.17) 1.01 (0.85-1.21) 1.19 (0.78-1.80) 0.91 (0.49-1.68) 1.03 (0.50-2.09)  
Hormone therapy used       
Ever/never 1.36 (1.28-1.46) 1.41 (1.30-1.53) 1.67 (1.36-2.05) 1.00 (0.75-1.34) 0.90 (0.64-1.28) 0.004 
Duration of use, per 5 year increase 1.20 (1.16-1.23) 1.21 (1.17-1.25) 1.25 (1.15-1.36) 1.09 (0.94-1.26) 0.69 (0.52-0.92) 0.00006 
Duration of use, years       
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤5 years 1.17 (1.07-1.27) 1.22 (1.09-1.36) 1.46 (1.11-1.91) 1.13 (0.78-1.63) 0.94 (0.61-1.44) 0.0005 
>5 years 1.60 (1.47-1.74) 1.75 (1.58-1.94) 1.90 (1.44-2.51) 1.06 (0.69-1.65) 0.51 (0.27-0.96)  
Tubal ligation, ever/never 0.82 (0.73-0.93) 0.91 (0.79-1.06) 0.60 (0.41-0.88) 1.01 (0.60-1.71) 0.35 (0.18-0.69) 0.005 
Hysterectomye, ever/never 1.11 (1.03-1.19) 1.18 (1.07-1.29) 1.14 (0.91-1.43) 0.83 (0.59-1.15) 0.62 (0.41-0.96) 0.005 
Endometriosis, ever/never 1.35 (1.07-1.71) 1.03 (0.74-1.46) 2.32 (1.36-3.95) 1.62 (0.58-4.51) 2.87 (1.53-5.39) 0.01 
a
Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of 
interest and then we adjusted only for the other risk factor) using pooled analyses of all cohorts combined.  
b
Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the association to vary by histologic subtype to a model forcing the association to be 
the same across subtypes.  
cParous women only. 
dPostmenopausal women only.  
e
Additionally adjusted for duration of hormone therapy use. 
Table 3: Associationsa of family history, demographic and lifestyle factors with invasive epithelial ovarian cancer overall and by subtypes in the Ovarian Cancer 
Cohort Consortium  
 All invasive Serous Endometrioid Mucinous Clear cell p-diff 
 N=5584 N=3378 N=606 N=331 N=269 (between 
Exposure RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) histologic types)
b 
First degree family history of breast cancer, 
1.09 (1.00-1.19) 1.13 (1.02-1.26) 1.47 (1.15-1.87) 0.73 (0.47-1.13) 0.75 (0.46-1.22) 0.008 
ever/never       
First degree family history of ovarian cancer, 
1.48 (1.26-1.75) 1.61 (1.32-1.97) 0.97 (0.52-1.82) 1.33 (0.59-3.00) 0.96 (0.36-2.57) 0.31 
ever/never       
Body mass index       
Per 5 kg/m
2 
1.01 (0.98-1.04) 0.97 (0.93-1.01) 1.07 (0.99-1.16) 1.08 (0.96-1.20) 1.04 (0.92-1.17) 0.06 
In kg/m
2 
      
<20 1.02 (0.91-1.13) 1.06 (0.92-1.21) 0.85 (0.60-1.19) 1.36 (0.90-2.04) 0.96 (0.60-1.53)  
20-<25 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
25-<30 0.97 (0.91-1.03) 0.91 (0.84-0.99) 0.97 (0.80-1.18) 1.42 (1.10-1.83) 1.21 (0.91-1.61) 0.10 
30-<35 0.99 (0.90-1.08) 0.92 (0.82-1.04) 1.09 (0.83-1.43) 1.23 (0.83-1.82) 0.97 (0.62-1.51)  
≥35 1.09 (0.97-1.24) 0.97 (0.83-1.14) 1.26 (0.88-1.80) 1.24 (0.69-2.21) 1.23 (0.70-2.15)  
Height       
Per 0.5m 1.06 (1.04-1.08) 1.06 (1.03-1.09) 1.06 (1.00-1.13) 1.04 (0.95-1.13) 1.08 (0.98-1.19) 0.94 
In meters       
<1.60 0.89 (0.83-0.96) 0.86 (0.78-0.95) 1.03 (0.82-1.29) 0.87 (0.64-1.18) 0.92 (0.65-1.30)  
1.60-<1.65 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
0.27 
1.65-<1.70 1.02 (0.95-1.10) 1.04 (0.95-1.14) 0.93 (0.74-1.17) 0.83 (0.61-1.13) 0.97 (0.70-1.36)  
≥1.70 1.12 (1.03-1.21) 1.06 (0.96-1.17) 1.27 (1.01-1.60) 1.12 (0.82-1.52) 1.24 (0.88-1.73)  
Smoking       
Ever/never 0.99 (0.94-1.05) 0.99 (0.92-1.06) 0.93 (0.79-1.09) 1.27 (1.01-1.59) 0.95 (0.74-1.21) 0.14 
Per 20 pack-years 0.98 (0.94-1.02) 1.01 (0.96-1.06) 0.92 (0.80-1.06) 1.20 (1.04-1.39) 0.68 (0.53-0.89) 0.002 
In pack-years       
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤10 1.07 (0.97-1.17) 1.07 (0.96-1.21) 1.02 (0.78-1.32) 1.14 (0.78-1.68) 0.95 (0.64-1.40)  
>10-20 1.02 (0.90-1.15) 1.04 (0.89-1.21) 0.72 (0.49-1.07) 1.40 (0.89-2.20) 0.88 (0.52-1.48) 0.09 
>20-35 0.96 (0.85-1.08) 0.99 (0.85-1.15) 0.92 (0.65-1.30) 1.16 (0.72-1.88) 0.44 (0.22-0.91)  
>35 0.99 (0.88-1.12) 1.08 (0.93-1.24) 0.85 (0.57-1.26) 1.60 (1.02-2.51) 0.42 (0.18-0.94)  
a
Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of 
interest and then we adjusted only for the other risk factor) using a pooled analysis of all cohorts combined.  
b
Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the association to vary by histologic subtype to a model forcing the association to be 
the same across subtypes. 
Table 4. Associationsa of risk factors with among serous ovarian carcinomas by grade in the Ovarian Cancer Cohort Consortium  
 Well- Moderately- Poorly- Unknown  
Exposure differentiated
b 
differentiated differentiated grade p-het.
c 
Parity      
Ever/never 0.78 (0.47-1.29) 0.77 (0.60-0.99) 0.83 (0.72-0.96) 0.88 (0.71-1.09) 0.87 
Number of children, per 1 child 0.89 (0.80-1.00) 0.90 (0.85-0.95) 0.94 (0.91-0.96) 0.96 (0.93-1.01) 0.20 
Number of children      
0 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
1 0.84 (0.41-1.73) 0.90 (0.64-1.27) 0.85 (0.69-1.05) 0.94 (0.70-1.26)  
2 0.88 (0.50-1.55) 0.86 (0.65-1.13) 0.89 (0.76-1.05) 0.89 (0.70-1.13) 0.42 
3 0.88 (0.50-1.54) 0.68 (0.51-0.91) 0.87 (0.74-1.03) 0.86 (0.67-1.10)  
4+ 0.45 (0.22-0.91) 0.68 (0.50-0.92) 0.69 (0.58-0.82) 0.89 (0.69-1.14)  
Oral contraceptive use      
Ever/never 1.11 (0.72-1.72) 0.80 (0.65-0.98) 0.85 (0.76-0.95) 0.77 (0.66-0.90) 0.36 
Duration of use, per 5 year increase 0.79 (0.62-1.00) 0.82 (0.73-0.92) 0.90 (0.84-0.96) 0.77 (0.69-0.87) 0.09 
Categorical duration of use (years)      
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤1 1.80 (0.98-3.30) 0.90 (0.63-1.29) 1.01 (0.84-1.20) 0.96 (0.74-1.24)  
>1-≤5 1.12 (0.65-1.94) 0.95 (0.72-1.25) 0.86 (0.74-1.00) 0.85 (0.68-1.06) 0.25 
>5-≤10 0.94 (0.48-1.83) 0.82 (0.60-1.13) 0.77 (0.65-0.92) 0.59 (0.44-0.79)  
>10 0.56 (0.22-1.42) 0.45 (0.28-0.73) 0.76 (0.61-0.94) 0.49 (0.34-0.71)  
Duration of breastfeeding, per 1 yeard 1.06 (0.68-1.66) 0.93 (0.75-1.15) 0.95 (0.83-1.08) 0.89 (0.74-1.08) 0.86 
Age at menarche (years)      
Per 1 year increase 1.01 (0.91-1.11) 1.00 (0.94-1.06) 1.01 (0.98-1.04) 0.95 (0.91-1.00) 0.21 
Categorical      
≤11 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
12 1.26 (0.70-2.28) 0.86 (0.64-1.14) 1.06 (0.91-1.23) 0.86 (0.69-1.06)  
13 1.37 (0.83-2.28) 0.94 (0.73-1.20) 1.10 (0.96-1.26) 0.76 (0.62-0.92) 0.22 
14 1.20 (0.62-2.34) 0.86 (0.62-1.18) 1.16 (0.97-1.38) 0.83 (0.65-1.05)  
≥15 1.00 (0.49-2.05) 0.99 (0.72-1.36) 0.94 (0.78-1.14) 0.80 (0.62-1.02)  
Age at menopause (years)      
Per 5 year increase 1.54 (1.23-1.91) 1.04 (0.93-1.16) 1.03 (0.97-1.10) 1.05 (0.95-1.16) 0.06 
Categorical      
≤45 0.20 (0.07-0.56) 0.92 (0.66-1.28) 0.91 (0.77-1.09) 0.89 (0.69-1.17)  
>45-≤50 0.49 (0.29-0.84) 1.21 (0.94-1.56) 0.96 (0.83-1.10) 0.98 (0.80-1.21) 0.02 
>50-≤55 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
>55 0.41 (0.13-1.32) 1.16 (0.73-1.84) 0.97 (0.75-1.24) 1.23 (0.87-1.73)  
HT usee      
Ever/never 1.80 (1.15-2.83) 1.57 (1.27-1.95) 1.49 (1.33-1.67) 1.23 (1.04-1.45) 0.15 
Duration of use, per 5 year increase 1.35 (1.18-1.53) 1.26 (1.17-1.36) 1.21 (1.16-1.26) 1.20 (1.12-1.29) 0.54 
Categorical duration of use (years)      
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤5 1.33 (0.71-2.48) 1.26 (0.94-1.69) 1.27 (1.09-1.48) 1.12 (0.90-1.41) 0.42 
>5 2.91 (1.72-4.92) 2.10 (1.60-2.76) 1.80 (1.56-2.07) 1.57 (1.27-1.95)  
Tubal ligation, ever/never 1.25 (0.66-2.36) 1.05 (0.71-1.57) 0.92 (0.76-1.11) 0.62 (0.43-0.88) 0.10 
Hysterectomy, ever/neverf 0.87 (0.53-1.42) 1.08 (0.86-1.35) 1.01 (0.89-1.15) 1.03 (0.86-1.24) 0.88 
Endometriosis, yes/no 3.77 (1.24-11.48) 1.54 (0.72-3.30) 1.11 (0.70-1.74) 0.57 (0.18-1.80) 0.12 
First degree family history of breast cancer, yes/no 1.23 (0.71-2.15) 1.20 (0.91-1.58) 1.12 (0.97-1.30) 0.96 (0.76-1.21) 0.58 
First degree family history of ovarian cancer, yes/no 0.90 (0.22-3.70) 1.46 (0.83-2.54) 1.63 (1.25-2.13) 1.64 (1.08-2.47) 0.82 
Body mass index (kg/m2)      
Per 5 kg/m
2 
0.92 (0.74-1.14) 0.99 (0.90-1.08) 0.92 (0.87-0.97) 1.05 (0.97-1.13) 0.03 
Categorical      
<20 1.33 (0.67-2.62) 0.78 (0.51-1.19) 1.15 (0.95-1.39) 1.11 (0.83-1.49)  
20-<25 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
25-<30 1.02 (0.65-1.59) 1.08 (0.88-1.33) 0.84 (0.74-0.94) 0.89 (0.75-1.05) 0.22 
30-<35 0.85 (0.44-1.66) 0.98 (0.73-1.32) 0.85 (0.72-1.00) 1.04 (0.83-1.32)  
≥35 1.15 (0.51-2.59) 0.88 (0.56-1.39) 0.88 (0.70-1.10) 1.25 (0.92-1.70)  
Height (meters)      
Per 0.5m 1.05 (0.93-1.18) 1.06 (0.99-1.14) 1.07 (1.03-1.11) 1.03 (0.97-1.08) 0.72 
Categorical      
<1.60 0.83 (0.49-1.39) 0.92 (0.72-1.17) 0.82 (0.72-0.95) 1.00 (0.82-1.21)  
1.60-<1.65 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 0.70 
1.65-<1.70 1.21 (0.75-1.95) 1.03 (0.81-1.30) 1.03 (0.91-1.18) 1.15 (0.95-1.39)  
≥1.70 0.96 (0.55-1.69) 1.08 (0.83-1.41) 1.06 (0.92-1.22) 0.96 (0.77-1.20)  
Smoking      
Ever/never 1.10 (0.85-1.41) 0.95 (0.84-1.07) 0.96 (0.90-1.03) 1.04 (0.95-1.15) 0.38 
Continuous pack-years, per 20 pack-years 0.87 (0.59-1.26) 1.00 (0.87-1.15) 0.98 (0.92-1.05) 1.07 (0.97-1.18) 0.44 
Categorical pack-years      
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)  
≤20 1.20 (0.70-2.08) 1.00 (0.76-1.32) 1.08 (0.94-1.24) 1.10 (0.88-1.36) 0.91 
>20 0.72 (0.34-1.52) 0.97 (0.71-1.31) 1.03 (0.89-1.21) 1.09 (0.87-1.38)  
a
Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of 
interest and then we adjusted only for the other risk factor) using pooled analyses of all cohorts combined. Excluding 5 cohorts with no information on grade for any ovarian cancer cases.  
b
Number of cases ranges from 28 (breastfeeding)-121 (OC use) for well-differentiated, 113 (Endometriosis)-496 (OC use) for moderately-differentiated, 338 (breastfeeding)-1637 (OC use) for 
poorly-differentiated, and 141 (endometriosis)-773 (OC use) for unknown grade.  
c
Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the association to vary by grade to a model forcing the association to be the same across 
grades. 
dParous women only. 
ePostmenopausal women only. 
fAdditionally adjusted for duration of hormone therapy use. 
Supplemental Table 1. Studiesa in the Ovarian Cancer Cohort Consortium contributing to each exposure analysis 
 
Variable 
 
Ever/never parous:  
Number of children (continuous or categorical): 
 
Ever/never OC use:  
Duration of OC use (continuous or categorical): 
 
Duration of breastfeeding (continuous):  
Age at menarche (continuous or categorical):  
Age at menopause (continuous and categorical): 
 
Ever use of HT  
Duration of HT use (continuous and 
categorical): 
 
Tubal ligation: 
 
Hysterectomy: 
 
Endometriosis: 
 
Family history of breast cancer: 
 
Family history of ovarian cancer: 
 
BMI (continuous and categorical): 
 
Height (continuous and categorical): 
 
Ever/never smoker:  
Pack-years of smoking (continuous and  
categorical): BCDDP, BGS, CPSII-NC, CSDLH, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, SMC, SS, VITAL, WHS 
a
Study abbreviations can be found in Table 1 
 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CTS, IWHS, MEC, NHS, NHSII, NLCS, PLCO, SCHS, SS, VITAL, WHS 
AARP, BCDDP, BGS, CLUE, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, SMC, SS, 
VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUE, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, SMC, SS, 
VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, SMC, 
SS, VITAL, WHS, WLHS 
 Studies 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, 
SMC, SS, VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SMC, 
SS, VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, 
SMC, SS, VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, 
SMC, SS, VITAL, WHS, WLHS 
BGS, CTS, EPIC, NHS, NHSII, SS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, 
SMC, SS, VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NLCS, NYU, PLCO, SCHS, SMC, 
SS, VITAL, WHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NLCS, NYU, PLCO, SCHS, SMC, 
SS, VITAL, WHS, WLHS 
AARP, BCDDP, BGS, CPSII-NC, CSDLH, EPIC, IWHS, MEC, NHS, NLCS, NYU, PLCO, SCHS, SMC, SS, VITAL, 
WHS 
CPSII-NC, CTS, EPIC, MEC, NHS, NHSII, NLCS, NYU, PLCO, SMC, SS, VITAL, WHS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, SCHS, 
SMC, SS, VITAL, WHS 
BGS, CTS, IWHS, NHSII, PLCO, SS 
AARP, BCDDP, BGS, CLUEII, CPSII-NC, CSDLH, CTS, EPIC, IWHS, MEC, NHS, NHSII, NLCS, NYU, PLCO, 
SCHS, SMC, VITAL, WHS 
Supplemental Table 2. Number of invasive epithelial ovarian cancer cases overall and by histologic subtype for each exposure  
Case numbers for each exposure Serous Endometrioid Mucinous Clear cell All Invasive 
Parity      
Ever/never 3300 598 318 254 5429 
Number of children (continuous or categorical) 3268 587 303 241 5351 
Oral contraceptive use      
Ever/never 3347 604 326 265 5523 
Duration of use (continuous or categorical) 3287 587 318 263 5418 
Duration of breastfeeding 831 157 70 63 1281 
Age at menarche (continuous or categorical) 3331 602 327 266 5489 
Age at menopause (postmenopausal only; continuous or categorical) 2162 345 207 132 3494 
HT use (postmenopausal only)      
Ever/never 2682 411 238 157 4319 
Duration of use (continuous or categorical) 2394 347 216 138 3802 
Tubal ligation 2387 435 213 193 3914 
Hysterectomy 3146 550 301 230 5486 
Endometriosis 900 169 73 86 1503 
First degree family history of breast cancer 3291 589 316 262 5383 
First degree family history of ovarian cancer 2634 459 238 205 4332 
Body mass index (continuous or categorical) 3234 578 319 262 5354 
Height (continuous or categorical) 3277 592 322 267 5433 
Smoking      
Ever/never 3335 605 328 268 5514 
Pack-years(continuous or categorical) 2257 416 223 191 4690 
Supplemental Table 3. Associationsa of risk factors with ovarian cancer subtypes based on meta-analysis pooling the results of individual studies in the Ovarian 
Cancer Cohort Consortium  
Exposure Serous Endometrioid Mucinous Clear cell 
Parity     
Ever/never 0.80 (0.73-0.89) 0.44 (0.36-0.55) 0.45 (0.31-0.64) 0.32 (0.24-0.43) 
Number of children, per 1 child 0.94 (0.92-0.96) 0.78 (0.72-0.84) 0.84 (0.75-0.95)
b 
0.65 (0.57-0.73) 
Number of children     
0 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
1 0.87 (0.74-1.02) 0.79 (0.58-1.07) 0.83 (0.48-1.45) 0.57 (0.36-0.91) 
2 0.87 (0.77-0.97) 0.47 (0.37-0.59) 0.52 (0.33-0.82) 0.41 (0.27-0.63) 
3 0.80 (0.71-0.90) 0.41 (0.32-0.54) 0.53 (0.34-0.80) 0.32 (0.19-0.52) 
4+ 0.72 (0.63-0.83) 0.33 (0.24-0.46) 0.60 (0.39-0.91) 0.31 (0.14-0.67) 
Oral contraceptive use     
Ever/never 0.82 (0.75-0.89) 0.88 (0.73-1.05) 1.04 (0.81-1.34) 0.74 (0.54-1.01) 
Duration of use, per 5 year increase 0.84 (0.78-0.90) 0.89 (0.77-1.02) 1.19 (0.99-1.43) 0.96 (0.82-1.12) 
Duration of use, years     
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
≤1 1.01 (0.88-1.16) 1.15 (0.86-1.55) 1.22 (0.77-1.91) 1.24 (0.74-2.06) 
>1-≤5 0.88 (0.78-0.99) 0.95 (0.74-1.23) 1.15 (0.77-1.71) 1.25 (0.78-2.01) 
>5-≤10 0.76 (0.65-0.89) 0.90 (0.67-1.21) 1.28 (0.84-1.95) 1.06 (0.67-1.68) 
>10 0.67 (0.57-0.79) 0.75 (0.97-1.16) 1.67 (1.06-2.64) 0.73 (0.36-1.45) 
Duration of breastfeeding, per 1 yearc 1.01 (0.87-1.18)
b 
0.93 (0.78-1.11) 0.94 (0.68-1.31) 1.13 (0.93-1.36) 
Age at menarche     
Per 1 year increase 0.99 (0.96-1.02) 1.00 (0.95-1.05) 1.00 (0.94-1.07) 0.94 (0.87-1.02) 
Age in years     
≤11 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
12 0.90 (0.75-1.08) 0.97 (0.74-1.27) 1.13 (0.75-1.70) 0.81 (0.54-1.22) 
13 0.99 (0.88-1.10) 1.00 (0.75-1.33) 1.05 (0.74-1.49) 0.84 (0.47-1.49) 
14 0.97 (0.85-1.12) 0.88 (0.63-1.23) 1.05 (0.65-1.68) 0.77 (0.46-1.27) 
≥15 0.91 (0.79-1.05) 1.02 (0.73-1.42) 1.37 (0.87-2.17) 0.80 (0.46-1.40) 
Age at menopause  
1.44 (1.08-1.93)
b 
1.04 (0.80-1.37)
b 
1.96 (1.37-2.81)
b 
Per 5 year increase 1.05 (1.00-1.10) 
Age in years     
≤40 1.02 (0.82-1.27) 0.79 (0.45-1.40) 2.02 (0.67-6.04) 0.64 (0.14-2.89) 
>40-≤45 0.88 (0.75-1.04) 1.03 (0.64-1.66) 1.10 (0.54-2.25) 0.95 (0.37-2.48) 
>45-≤50 0.96 (0.86-1.06) 0.86 (0.65-1.13) 0.96 (0.68-1.35) 1.06 (0.69-1.63) 
>50-≤55 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
>55 1.05 (0.88-1.25) 1.35 (0.88-2.08) 1.66 (0.83-3.34) 1.93 (0.88-4.23) 
HT used     
Ever/never 1.40 (1.27-1.55) 1.81 (1.41-2.32) 1.04 (0.77-1.41) 0.90 (0.57-1.42) 
Duration of use, per 5 year increase 1.22 (1.15-1.29) 1.33 (1.17-1.51) 1.08 (0.86-1.36) 0.69 (0.49-0.98)
b 
Duration of use, years     
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
≤5 1.24 (1.11-1.38) 1.71 (1.20-2.43) 1.27 (0.87-1.85) 1.06 (0.63-1.75) 
>5 1.75 (1.55-1.98) 2.32 (1.59-3.38) 1.43 (0.89-2.30) 0.83 (0.55-1.25) 
Tubal ligation, ever/never 0.97 (0.81-1.16) 0.79 (0.53-1.18) 1.43 (0.80-2.56) 0.63 (0.27-1.46) 
Hysterectomy, ever/nevere 1.18 (0.79-1.76)
b 
1.21 (0.64-2.30)
b 
1.09 (0.61-1.95)
b 
0.95 (0.55-1.63) 
Endometriosis, yes/no 1.14 (0.81-1.61) 2.84 (1.56-5.18) 5.06 (1.51-16.9) 3.43 (1.52-7.75) 
First degree family history of breast cancer, yes/no 1.19 (1.02-1.39) 1.56 (1.22-1.99) 1.04 (0.67-1.61) 1.29 (0.78-2.13) 
First degree family history of ovarian cancer, yes/no 1.16 (0.43-3.18)
b 
0.29 (0.01-5.89)
b 
0.01 (0.00-1.13)
b 
0.02 (0.00-1.68)
b 
Body mass index     
Per 5 kg/m
2 
0.97 (0.93-1.01) 1.03 (0.92-1.15)
b 
1.08 (0.97-1.20) 0.95 (0.80-1.14)
b 
In kg/m
2 
    
<20 1.08 (0.94-1.24) 1.18 (0.83-1.67) 1.97 (1.28-3.02) 1.50 (0.92-2.44) 
20-<25 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
25-<30 0.93 (0.84-1.03) 1.00 (0.82-1.23) 1.44 (1.11-1.87) 1.37 (1.01-1.84) 
30-<35 0.94 (0.83-1.06) 1.28 (0.97-1.70) 1.86 (1.22-2.86) 1.77 (1.04-3.00) 
≥35 1.07 (0.84-1.35) 1.73 (1.20-2.50) 2.18 (1.09-4.36) 2.26 (1.19-4.29) 
Height   
1.08 (0.96-1.19)
b 
 
Per 0.5m 1.06 (1.03-1.10) 1.06 (0.99-1.13) 1.08 (0.98-1.17) 
In meters     
<1.60 0.87 (0.79-0.96) 1.05 (0.83-1.32) 0.98 (0.71-1.34) 1.02 (0.71-1.46) 
1.60-<1.65 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
1.65-<1.70 1.05 (0.94-1.19) 1.00 (0.79-1.27) 1.02 (0.73-1.41) 1.02 (0.67-1.58) 
≥1.70 1.06 (0.96-1.17) 1.28 (1.01-1.63) 1.23 (0.88-1.71) 1.23 (0.85-1.78) 
Smoking     
Ever/never 1.02 (0.92-1.12) 0.95 (0.80-1.12) 1.25 (0.99-1.57) 0.92 (0.70-1.21) 
Continuous pack-years, per 20 pack-years 1.03 (0.97-1.10) 0.98 (0.84-1.15) 1.21 (1.04-1.40) 0.79 (0.59-1.05) 
Categorical pack-years     
Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
≤10 1.12 (0.99-1.27) 1.21 (0.91-1.59) 1.29 (0.86-1.93) 1.04 (0.67-1.63) 
>10-20 1.09 (0.92-1.28) 0.91 (0.61-1.37) 1.62 (0.96-2.72) 1.25 (0.66-2.37) 
>20-35 1.08 (0.87-1.32) 1.12 (0.77-1.63) 1.53 (0.89-2.61) 0.94 (0.42-2.11) 
>35 1.13 (0.94-1.35) 1.20 (0.78-1.85) 2.13 (1.27-3.55) 0.98 (0.40-2.40) 
a
Stratified on birth year, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and 
then we adjusted only for the other risk factor).  
b
Meta-analysis p-heterogeneity across studies <0.01 using the q-statistic from a random-effects meta-analysis. 
c
Parous 
women only.  
d
Postmenopausal women only. eAdditionally adjusted for duration of hormone therapy use.
 
